328 related articles for article (PubMed ID: 25124273)
1. Metabolism in HD: still a relevant mechanism?
Duan W; Jiang M; Jin J
Mov Disord; 2014 Sep; 29(11):1366-74. PubMed ID: 25124273
[TBL] [Abstract][Full Text] [Related]
2. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
5. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.
Mihm MJ; Amann DM; Schanbacher BL; Altschuld RA; Bauer JA; Hoyt KR
Neurobiol Dis; 2007 Feb; 25(2):297-308. PubMed ID: 17126554
[TBL] [Abstract][Full Text] [Related]
6. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
Wang H; Lim PJ; Karbowski M; Monteiro MJ
Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
[TBL] [Abstract][Full Text] [Related]
7. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism.
Lee JM; Ivanova EV; Seong IS; Cashorali T; Kohane I; Gusella JF; MacDonald ME
PLoS Genet; 2007 Aug; 3(8):e135. PubMed ID: 17708681
[TBL] [Abstract][Full Text] [Related]
8. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.
Oliveira JM
J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration.
Oliveira JM
J Bioenerg Biomembr; 2010 Jun; 42(3):227-34. PubMed ID: 20454921
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets and therapeutic strategies in Huntington's disease.
Rego AC; de Almeida LP
Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):361-81. PubMed ID: 16101555
[TBL] [Abstract][Full Text] [Related]
11. Bioenergetics in Huntington's disease.
Grünewald T; Beal MF
Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
[TBL] [Abstract][Full Text] [Related]
12. Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.
Quintanilla RA; Johnson GV
Brain Res Bull; 2009 Oct; 80(4-5):242-7. PubMed ID: 19622387
[TBL] [Abstract][Full Text] [Related]
13. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
[TBL] [Abstract][Full Text] [Related]
14. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release.
Choo YS; Johnson GV; MacDonald M; Detloff PJ; Lesort M
Hum Mol Genet; 2004 Jul; 13(14):1407-20. PubMed ID: 15163634
[TBL] [Abstract][Full Text] [Related]
15. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
16. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
[TBL] [Abstract][Full Text] [Related]
17. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.
Naia L; Ribeiro MJ; Rego AC
Rev Neurosci; 2011 Dec; 23(1):13-28. PubMed ID: 22150069
[TBL] [Abstract][Full Text] [Related]
19. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
[TBL] [Abstract][Full Text] [Related]
20. PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.
Tsunemi T; La Spada AR
Prog Neurobiol; 2012 May; 97(2):142-51. PubMed ID: 22100502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
